BME:ALMPharmaceuticals
Is China’s Seysara Approval and Sinomune Deal Altering The Investment Case For Almirall (BME:ALM)?
Almirall has reported that China’s National Medical Products Administration approved Seysara (sarecycline hydrochloride) for treating inflammatory lesions of non-nodular moderate-to-severe acne in patients aged 9 and older, with Sinomune holding exclusive commercialization and distribution rights in China.
This marks the first approval in China of a tetracycline-derived oral antibiotic developed specifically for dermatology, expanding Seysara’s reach beyond its earlier US launch and...